Article

Generic drug sale blocked until 2009

A federal appellate court has blocked the largest Canadian-owned pharmaceutical company from manufacturing and selling a generic version of Allergan's ketorolac tromethamine ophthalmic solution 0.5% (Acular).

Irvine, CA-A federal appellate court has blocked the largest Canadian-owned pharmaceutical company from manufacturing and selling a generic version of Allergan's ketorolac tromethamine ophthalmic solution 0.5% (Acular).

The ruling, by the United States Court of Appeals for the Federal Circuit, upholds a lower-court ruling in favor of Allergan and Roche Palo Alto LLC (formerly known as Syntex). That ruling found that Apotex Inc., Apotex Corp., and Novex Pharma had infringed a valid and enforceable patent owned by Roche Palo Alto and licensed to Allergan.

The solution is used to treat ocular itching related to seasonal allergic conjunctivitis or for the treatment of postoperative inflammation following cataract surgery.

The companies are prevented from making any preparations that make, use, sell, or offer for sale ketorolac tromethamine ophthalmic solution 0.5% in the United States.

Apotex Corp. is the U.S. subsidiary of Apotex Inc., the largest Canadian-owned manufacturer of prescription drugs. Novex Pharma is part of the Apotex Group of Companies.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.